Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma · Immunotherapy · Biomarkers

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Contact: Study coordinator (Yong Yang, Doctor) · dr_yangyong1983@163.com · 18813019084

Study leads

Yong Yang, Doctor
Principal Investigator
Fujian Medical University Union Hospital
Lei Zhao
Principal Investigator
Sun Yat-Sen University Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Xi'an, China

Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

Esophageal Squamous Cell Carcinoma (ESCC) · Immunotherapy

Abroad (travel likely)RecruitingPHASE2

Chengdu, China

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma · Neoadjuvant Chemoimmunotherapy · Adjuvant Therapy

Abroad (travel likely)RecruitingPHASE2

Shanghai, China